Retailers fined for dodgy Black Friday sales
Jeweller Michael Hill, homewares retailer Global Retail Brands Australia, and Hairhouse Online have each paid a $19,800 fine following infringement notices from the Australian Competition and Consumer Commission (ACCC), the regulator says.
Paying fines does not amount to an admission of breaking the Australian Consumer Law.
The consumer watchdog issued the infringement notices after finding the retailers were selling non-discounted items despite their website homepages spruiking 'sitewide' sales or sales on 'everything'.
The discrepancies were found during a sweep the ACCC did of Black Friday sales, the period at the end of November where retailers typically have large discounts.
'Businesses that make false discount claims not only risk misleading consumers, they also compete unfairly against other businesses which correctly state the nature of their sales,' ACCC deputy chair Catriona Lowe said.
ACCC analysis shows that while Michael Hill had a prominent banner on its homepage promoting a 'member event' 25 per cent off sitewide sale, some items were not discounted.
'Michael Hill's statement may have misled consumers, and contravened the Australian Consumer Law, because some of the products in its online store were not part of the sale and were not discounted,' Ms Lowe said.
Global Retail Brands Australia owns MyHouse, which has 28 physical stores in Australia, plus a range of similar homewares businesses.
Splashed across the MyHouse e-store late last year was an ad saying 'everything' was subject to a Black Friday sale with discounts up to 60 per cent. The ad also promised an 'extra' 20 per cent off.
'We say this was misleading because the extra 20 per cent discount was not available on all of its products,' Ms Lowe said.
'Retailers need to ensure that their advertising makes it clear to consumers which products are discounted and by how much.'
Hairhouse Online promised 20 to 50 per cent off 'sitewide' for Black Friday sales. More than one-quarter of items on the site were not discounted at all, the ACCC says.
The haircare retailer is owned by Melbourne-based The Hairhouse Warehouse.
Australians spent about $7bn on the Black Friday sales in 2024.
NewsWire has contacted the three companies for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
SYDNEY, AUSTRALIA, July 28, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces three abstracts for clinical trials evaluating its first-in-class MHC Class II agonist, eftilagimod alfa (efti), have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025 taking place 17-21 October in Berlin, Germany. A Proffered Paper oral presentation will detail results from EFTISARC-NEO, a Phase II investigator-initiated trial in resectable soft tissue sarcoma, and data from the INSIGHT-003 Phase I investigator-initiated trial in first-line non-small cell lung cancer (1L NSCLC) has been accepted for poster presentation. Additionally, an abstract on the Company's pivotal TACTI-004 Phase III in 1L NSCLC has been accepted for a Trials in Progress ePoster. Details of the presentations are as follows: Title: EFTISARC-NEO: A phase II study of neoadjuvant eftilagimod alpha, pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma Presenter: Katarzyna Kozak, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland Session Category: Proffered Paper Session Title: Sarcoma Presentation #: 2686O Date and Time: Sunday, 19 October 2025 at 16:30 – 18:00 PM CET Title: Eftilagimod alpha (soluble LAG-3 protein) combined with 1st line chemo-immunotherapy in metastatic non-squamous non-small cell lung cancer (NSCLC) –Updates from INSIGHT-003 (IKF614) Presenter: Dr. med. Akin Atmaca, Department of Hematology and Oncology, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany Session Category: Poster Session Title: NSCLC, metastatic Presentation #: 1857P Date and Time: Saturday, 18 October 2025 at 12:00 – 12:45 PM CET Title: TACTI-004, a double-blinded, randomised phase 3 trial of eftilagimod alfa plus pembrolizumab (P) + chemotherapy (C) vs placebo + P + C in 1st line advanced/metastatic NSCLC Presenter: Prof. Dr. med. Hans-Georg Kopp, Robert Bosch Hospital, Stuttgart, Germany Session Category: ePoster Session Title: NSCLC, metastatic Presentation #: 2086eTiP Proffered Papers at ESMO are oral presentations of original data of superior quality, followed by expert discussion and perspectives. Abstracts will be made available on the ESMO website on 13 October 2025 at 00.05 CET. The posters will be available on the Posters & Publications section of Immutep's website after their presentations. About ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; U.S. Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000;
Yahoo
2 minutes ago
- Yahoo
Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)
Lu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3 On track to initiate first-in-human study of RV-01 in solid tumors in 4Q25 SYDNEY, July 28, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, 'Radiopharm' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has provided clearance of the Company's Investigational New Drug (IND) application for Betabart (RV-01), its Lu177-B7H3 monoclonal antibody designed with strong affinity for the 4Ig isoform of B7H3 that is highly expressed in tumors and not in healthy tissues. 'FDA clearance to initiate our first-in-human Phase 1 clinical trial of RV-01 represents a major milestone for Radiopharm Theranostics and our joint venture with MD Anderson Cancer Center,' said Riccardo Canevari, CEO and Managing Director. 'RV-01 is the first monoclonal antibody developed through this collaboration, and we believe it has the potential to become a highly differentiated radiopharmaceutical for patients with aggressive solid tumors. We are excited to advance this program into the clinic and anticipate dosing the first patients later this year.' 'Recent reported preclinical studies demonstrated that RV-01 exhibits hepatic clearance, allowing the isotope sufficient time to effectively target tumors while potentially minimizing adverse effects such as hematological toxicities. Unlike peptides or small molecules, monoclonal antibodies are primarily cleared by the liver—an organ known for its radio-resistance. This characteristic, combined with the shortened half-life of RV-01 and the strong affinity for the target make this agent stand out and may offer a significant advantage not just over other monoclonal antibodies but also targeted radiotherapeutics with renal excretion pathway, the latter of which are often associated with higher risk of radiopharmaceutical-induced kidney toxicity,' noted Dimitris Voliotis, M.D., Chief Medical Officer of Radiopharm Theranostics. 'The high affinity and selectivity of RV-01 for the 4Ig isoform of B7H3 allows the antibody to bypass the soluble 2Ig isoform in the blood, boost binding of the radiopharmaceutical to tumor targets and avoid the formation of immune complexes in circulation,' noted David Piwnica-Worms, M.D., Ph.D., Professor, MD Anderson Cancer Center, and scientific co-founder of Radiopharm Ventures. B7-H3 is an immune checkpoint molecule that is overexpressed across several tumor types and has emerged as a compelling target for antibody-based cancer immunotherapy. Deregulated B7-H3 expression is consistently correlated with enhanced tumor aggressiveness and poor clinical outcomes. Targeting the 4 Ig isoform of B7-H3 with a selective radioligand therapy may offer a novel strategy for treating refractory or high-risk tumors. About RV-01 RV-01 is the first radiopharmaceutical therapeutic agent developed by Radiopharm Ventures, the Joint Venture formed between Radiopharm Theranostics and MD Anderson Cancer Center (MDACC). RV-01 is a 177Lutetium-conjugated therapeutic that targets B7-H3, an immune checkpoint molecule that is overexpressed in several tumor types. Multiple preclinical studies with RV-01 have shown tumor shrinkage and prolonged survival in animals treated with the radiotherapeutic agent. RV-01 has received IND-clearance from the U.S. FDA and plans to initiate a first-In-human Phase 1 study in the second half of 2025. About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. For more information: Investors:Riccardo CanevariCEO & Managing DirectorP: +1 862 309 0293E: rc@ Anne Marie FieldsPrecision AQ (formerly Stern IR)E: Media:Matt WrightNWR CommunicationsP: +61 451 896 420E: matt@ Follow Radiopharm Theranostics: Website – X – – –
Yahoo
32 minutes ago
- Yahoo
Bubs Australia appoints former Fonterra executive as new CEO
Bubs Australia has appointed its second CEO in almost two years, naming former Fonterra executive Joe Coote to head up the infant-formula maker. Coote takes up the role with immediate effect, Bubs said in a stock exchange filing today (28 July). Reg Weine, who became CEO in August 2023, is leaving the company. Weine had replaced interim chief Richard Paine, who stepped in to fill the role when founder and former chief executive Kristy Carr was axed in May of that year. Coote brings over 20 years of leadership experience in the FMCG sector, including dairy and infant nutrition. Most recently, he was CEO of Darigold, the fourth-largest dairy cooperative in the US, overseeing more than $2bn in global sales, according to the filing. Prior to that, he spent 12 years at Asia-Pacific dairy giant Fonterra, including president of the US division. Bubs' chair Katrina Rathie said: "We are confident Joe will execute Bubs' domestic and international growth ambitions with discipline and agility to create sustainable value for our shareholders. "His proven track record in driving operational excellence and leading large-scale transformations across international markets will be instrumental in expanding our premium clean-label goat and grass-fed dairy product portfolio across key export destinations, including the USA, China and other Asian markets." Coote will be paid an annual salary of A$750,000 ($489,452m), according to the filing. The incoming CEO said: 'After 15 years abroad building global brands, it's a privilege to return home and channel my experience into leading an Australian brand that's redefining premium infant nutrition. "I'm excited to lead the Bubs' team to build a world-class infant-nutrition brand that delivers exceptional outcomes for our shareholders and families the world over.' Bubs also issued its unaudited financial results today for the 2025 fiscal year. Established in 2006, the company produces the brands A2 Beta-Casein Protein, Organic Grass-fed, and Easy-Digest Goat Milk Infant Formula, as well as an organic baby food range. Revenue rose 29% to A$102.5m. However, its gross profit margin dropped by 140 basis points to 47.2%. In the US, described as the company's 'best-performing market', Bubs registered 52% revenue growth, generating A$53m by leveraging the 'growing premium IMF segment'. In China, net revenue grew by 22%, reflecting 'strong' cross-border e-commerce sales of goat and supreme formulas. In Australia, net revenue rose by 8%, while the rest of the world markets, including Vietnam and Japan, saw a 44% increase. The company projects a full-year EBITDA of A$5.5m to A$6m, a turnaround from the previous year's A$19.8m loss. "Bubs Australia appoints former Fonterra executive as new CEO" was originally created and published by Just Food, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
